Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novakand Pharma ABFRA:3EE0 Cash Ratio is 9.65 as of Dec. 2025, which is 75% above its 10-year median of 5.51. The stock has 1 warning sign investors should review.
Novakand Pharma AB has a Cash Ratio of 9.65. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Novakand Pharma AB's Cash Ratio or its related term are showing as below:
FRA:3EE0'
s Cash Ratio Range Over the Past 10 Years
Min: 0.45 Med: 5.51 Max: 10.21
Current: 9.63
During the past 13 years, Novakand Pharma AB's highest Cash Ratio was 10.21. The lowest was 0.45. And the median was 5.51.
FRA:3EE0's Cash Ratio is not ranked
in the Biotechnology industry.
Industry Median: 3
vs FRA:3EE0: 9.63
Novakand Pharma AB (FRA:3EE0) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Novakand Pharma AB Cash Ratio Related Terms
Novakand Pharma AB Cash Ratio Historical Data
* Premium members only.
The historical data trend for Novakand Pharma AB's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:3EE0 vs VRTX, REGN, ALNY: Cash Ratio Comparison
For the Biotechnology subindustry, Novakand Pharma AB's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novakand Pharma AB Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Novakand Pharma AB's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Novakand Pharma AB's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novakand Pharma AB (FRA:3EE0) has a Cash Ratio of 9.65 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Novakand Pharma AB and its competitors. This is 75% above median its historical median of 5.51. Over the past decade, Novakand Pharma AB's Cash Ratio has ranged from 0.45 to 10.21.
Is Novakand Pharma AB's Cash Ratio too high?
Novakand Pharma AB's current Cash Ratio of 9.65 is 75% above median its 10-year median of 5.51. Over the past 10 years, this metric has ranged from a low of 0.45 to a high of 10.21. The Biotechnology industry median Cash Ratio is 3.00. Novakand Pharma AB's value of 9.65 is 221.7% above this industry median.
How does Novakand Pharma AB's Cash Ratio compare to VRTX and REGN?
Novakand Pharma AB's Cash Ratio of 9.65 can be compared against companies in the Biotechnology industry. The industry median Cash Ratio is 3.00. Novakand Pharma AB's value of 9.65 is 221.7% above this benchmark. Historically, Novakand Pharma AB's own Cash Ratio has ranged from 0.45 to 10.21 over the past decade. While the company's 10-year median is 5.51 vs. the industry median of 3.00, Novakand Pharma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 3.00, based on 1,341 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novakand Pharma AB's current Cash Ratio of 9.65 is 221.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Novakand Pharma AB and its competitors. For the Biotechnology industry, the median Cash Ratio is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novakand Pharma AB's current Cash Ratio is 9.65, which is 75% above median its own 10-year median of 5.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novakand Pharma AB stock overvalued right now?
Novakand Pharma AB (FRA:3EE0) has a current Cash Ratio of 9.65. The current Cash Ratio is 9.65, which is 75% above median its 10-year median of 5.51 and 221.7% above the Biotechnology industry median of 3.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Novakand Pharma AB (FRA:3EE0), the current Cash Ratio is 9.65 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Novakand Pharma AB is developing a new class of innovative drugs focusing on inflammatory diseases and cancer. The company is developing a new class of small molecule drugs that control disease promoting immune cells with precision, by targeting the fractalkine axis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3EE0 has been successfully added to your 
